Rheumatoid Arthritis

Clinical Snapshot

Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease in which loss of immune tolerance drives inflammatory synovitis — most often a symmetric polyarthritis of the small joints of the hands and feet — that progresses to cartilage and bone erosion, joint deformity, and disability if left uncontrolled. Radiographic erosions can appear within the first year of untreated disease, which is why current guidance directs starting disease-modifying therapy immediately at diagnosis rather than simply controlling symptoms.^[1] RA also carries systemic disease burden independent of joint involvement — an increased risk of cardiovascular disease comparable to diabetes mellitus, osteoporosis, lymphoproliferative disease, interstitial lung disease, and depression — so routine RA care includes actively screening for and managing these comorbidities, not just the joints.

Recognize the Condition

The hallmark presentation is a symmetric, additive polyarthritis most often involving the small joints of the hands (metacarpophalangeal and proximal interphalangeal joints, characteristically sparing the distal interphalangeal joints) and feet, plus the wrists — accompanied by morning stiffness lasting more than 30 minutes that improves with activity through the day. Pain, swelling, warmth, and tenderness on exam reflect active synovitis; over time, unresolved synovitis produces joint erosion, subluxation, and characteristic deformities (ulnar deviation, swan-neck and boutonnière deformities). Fatigue is a near-universal and often disabling symptom, frequently out of proportion to visible joint findings.

Extra-articular manifestations by system

Ocular

Dry eyes (secondary Sjögren syndrome), episcleritis, and scleritis — scleritis can threaten vision and needs urgent ophthalmology assessment.

Pulmonary

Interstitial lung disease, pleural effusion, and pulmonary rheumatoid nodules.

Dermatologic

Rheumatoid nodules at pressure points — commonly the olecranon, extensor forearm, and back of the heel.

Hematologic/lymphatic

Anemia of chronic disease, lymphadenopathy, and an increased baseline risk of lymphoma independent of any specific therapy.

Neurologic

Carpal tunnel syndrome from wrist synovitis/tenosynovitis, and cervical spine (atlantoaxial, C1-C2) subluxation in longstanding disease — a genuine airway and spinal-cord risk during intubation or neck manipulation that must be flagged before any procedure.

Cardiovascular

Accelerated atherosclerosis and pericarditis.

Vasculitic

Rheumatoid vasculitis — rare, but a severe complication of longstanding seropositive disease that can affect skin, peripheral nerves, and other organs.

Risk Factors

Genetic susceptibility, including HLA-DRB1 "shared epitope" alleles.
Cigarette smoking — the strongest modifiable risk factor, and one that also reduces DMARD treatment response.
Female sex.
Family history of RA or another autoimmune disease.
Obesity.
Periodontal disease — implicated in triggering the citrullination process linked to RA autoimmunity.
Onset can occur at any age, including childhood, but most commonly begins in the fifth to sixth decade of life.

Red Flags & Refer

Any new joint swelling or inflammatory joint pain consistent with RA needs urgent rheumatology referral — ideally within 6 weeks of symptom onset — because early, aggressive treatment changes long-term outcomes; treat this itself as a standing red flag, not only the items below.^[1]

Serious infection (especially one requiring IV antibiotics or hospitalization) in a patient on a bDMARD, tsDMARD, or csDMARD — hold the immunosuppressive therapy until the infection resolves; do not continue dosing through it.
Symptoms suggesting tuberculosis reactivation or new hepatitis B/C reactivation (fatigue, jaundice, abnormal liver enzymes) in a patient on or starting a bDMARD/tsDMARD.
New scleritis, sudden severe abdominal pain (possible gastrointestinal perforation — a recognized IL-6 inhibitor complication), or signs of a serious infusion/injection hypersensitivity reaction.
New neurologic deficit, especially with neck movement or after trauma — suspect atlantoaxial (C1-C2) subluxation, which can compress the cervical spinal cord and is a specific anesthesia/intubation hazard that must be flagged before any procedure or surgery.
Signs of leflunomide-associated severe hepatotoxicity (jaundice, right-upper-quadrant pain, dark urine) — leflunomide has caused fatal liver injury; hold the drug and initiate the cholestyramine washout protocol if suspected.
Signs of methotrexate pulmonary toxicity (new dyspnea, dry cough, fever) or bone marrow suppression (unexplained bruising, bleeding, fever, mouth ulcers) — hold methotrexate and investigate urgently.
New or worsening chest pain, leg swelling, or dyspnea in a patient on a JAK inhibitor — assess for venous thromboembolism/pulmonary embolism and major adverse cardiovascular events, both boxed-warning risks for this drug class.^[2]
Suspected progressive multifocal leukoencephalopathy (new neurologic, cognitive, or visual symptoms) in a patient on rituximab — rare but reported.
New or unexplained lymphadenopathy or weight loss suggesting lymphoproliferative disease.

Assessment & Diagnosis

Differentiating RA from its common mimics

RA is most often confused with other causes of joint pain and swelling — distinguishing them changes the entire treatment approach.

Feature	Rheumatoid arthritis	Osteoarthritis	Psoriatic arthritis	Acute gout	Viral (reactive) arthritis
Joint pattern	Symmetric small joints (MCP, PIP, wrist), sparing the DIP joints	DIP/PIP, 1st CMC, hips, knees — typically asymmetric	Asymmetric; DIP involvement common; dactylitis ("sausage digit")	Classically monoarticular, 1st MTP ("podagra"); can become polyarticular with chronic tophaceous disease	Symmetric small joints; often self-limited
Morning stiffness	More than 30-60 minutes	Under 30 minutes; worsens through the day with use	Variable	Brief — acute pain dominates over stiffness	Variable, usually brief
Systemic/extra-articular features	Fatigue, rheumatoid nodules, extra-articular organ involvement	None	Psoriasis, nail pitting/onycholysis, enthesitis, dactylitis	Tophi with chronic disease	Preceding viral prodrome, rash, lymphadenopathy
Key serology	Rheumatoid factor and/or anti-CCP often positive	Normal inflammatory markers	Typically seronegative	Synovial fluid negatively birefringent monosodium urate crystals; serum urate often elevated (can be normal during an acute flare)	Positive viral serology; self-limited course over weeks
Imaging	Periarticular osteopenia, marginal erosions	Joint space narrowing, osteophytes, subchondral sclerosis	"Pencil-in-cup" deformity, periostitis, enthesitis	Punched-out erosions with an overhanging edge	Normal

History

Severity of joint pain, duration of morning stiffness, physician and patient global assessment of disease activity, and functional limitation (e.g., a Health Assessment Questionnaire).

Physical examination

Number of actively inflamed/swollen joints; mechanical problems (loss of motion, crepitus, instability, malalignment, deformity); extra-articular findings (dry eyes, rheumatoid nodules at pressure points, pulmonary findings, carpal tunnel signs).

Investigations

Anti-CCP (anti-cyclic citrullinated peptide, also reported as ACPA) and rheumatoid factor (RF) — a negative result for either does not exclude RA.
CBC, CRP, ESR, liver panel, and serum creatinine — baseline organ-function assessment before starting DMARD therapy, and CRP/ESR to support the diagnosis and track disease activity over time.
Radiographs of the hands and feet — often normal early in disease; erosions typical of RA are sufficient to confirm the diagnosis when present, but their absence does not rule RA out.

2010 ACR/EULAR classification criteria

Objective joint swelling (by exam or imaging) must be present before applying these criteria, which support a timely diagnosis when typical erosive changes are not yet present. Score categories A-D; a total of 6 or more out of 10 supports a definite diagnosis of RA.^[3]

Classification criteria	Score
A. Joint involvement
1 large joint	0
2-10 large joints	1
1-3 small joints	2
4-10 small joints	3
More than 10 joints (at least 1 small joint)	5
B. Serology (at least 1 result needed)
Negative RF and negative anti-CCP	0
Low-positive RF or low-positive anti-CCP	2
High-positive RF or high-positive anti-CCP	3
C. Acute-phase reactants (at least 1 result needed)
Normal CRP and normal ESR	0
Abnormal CRP or abnormal ESR	1
D. Duration of symptoms
Under 6 weeks	0
6 weeks or more	1

"Large joints" are shoulders, elbows, hips, knees, and ankles; "small joints" are the metacarpophalangeal, proximal interphalangeal, 2nd-5th metatarsophalangeal, thumb interphalangeal, and wrist joints. This is a closed, published points-based classification tool intended for a consistent case definition, and is presented here as a teaching table rather than an interactive calculator, since applying it correctly requires a hands-on joint examination.^[3]

Poor prognostic factors

The presence of these factors supports more intensive initial therapy and closer follow-up.

Non-modifiable: moderate-high disease activity by a composite or individual measure; presence of RF and/or anti-CCP, especially at high titer; erosions present on baseline radiograph; failure of 2 or more csDMARDs; a high degree of physical disability at onset.
Modifiable: smoking; a sedentary lifestyle; delay in starting treatment.

Treatment Targets

Achieve at least 50% clinical improvement within 3 months of starting therapy.
Achieve remission — or, if remission is not attainable, low disease activity — by 6 months, tracked with a validated composite measure (see Monitoring & Follow-Up).
Fully control signs and symptoms: pain, stiffness, and fatigue.
Halt radiographic progression and joint damage.
Maintain physical function, work capacity, and quality of life.
Adjust therapy at every visit against the defined target — never continue an unchanged regimen simply because the patient is "stable but not at target."

Choose Initial Treatment

Direct treatment rule

Confirmed RA, 1st line start methotrexate 10-15 mg PO or SC once weekly, titrated toward a maximum of 25 mg weekly over 4-8 weeks, with folic acid — the anchor csDMARD for essentially every patient without a contraindication.^[1]

Methotrexate contraindicated start sulfasalazine or hydroxychloroquine monotherapy instead, particularly for early, mild disease without poor prognostic factors.

Bridging add a short course of systemic corticosteroid (prednisone 30 mg/day PO, tapering over 6-12 weeks, or a single IM depot injection) at the lowest effective dose whenever initiating or changing a csDMARD, to control symptoms while the csDMARD takes full effect.^[4]

Methotrexate monotherapy inadequate at 3 months, moderate-high disease activity on maximal tolerated dose add a biologic or targeted synthetic DMARD, conditionally preferred over switching to triple csDMARD therapy (methotrexate + sulfasalazine + hydroxychloroquine) given faster symptom control, even though long-term outcomes and cost favor triple therapy in trial data — triple therapy remains an entirely appropriate alternative.^[5]

Before starting any bDMARD or tsDMARD complete tuberculosis and hepatitis B/C screening and confirm immunizations are current (see Monitoring & Follow-Up) — do not start immunosuppression before this is done.

Do not default to a JAK inhibitor as the first non-csDMARD step in a patient 65 or older, a current or past smoker, or with additional cardiovascular risk factors or a malignancy history — reserve JAK inhibitor therapy in this population for inadequate response to, or intolerance of, at least 1 TNF inhibitor.^[2]

Non-Pharmacologic Treatment

Multidisciplinary team care — rheumatology, physical/occupational therapy, and patient education — improves outcomes beyond medication alone.
Physical activity across all 4 domains (cardiorespiratory fitness, muscle strength, flexibility, and neuromotor performance) is safe and beneficial in RA and belongs in every treatment plan, not restricted because of joint disease.^[1]
Energy conservation counselling, joint protection techniques, and pacing of activities and work roles.
Heat and cold application for symptomatic pain modulation.
Periodic evaluation for splints, foot orthoses, and proper footwear; surgical referral for severely damaged joints.
Dietary omega-3 polyunsaturated fatty acids may provide a modest benefit on disease activity as an adjunct — not a substitute for DMARD therapy.
There is insufficient evidence to support complementary/alternative therapies, and no evidence to support cannabis, for RA disease control.
Smoking cessation — reduces cardiovascular risk and improves DMARD treatment response.

Pharmacologic Treatment Options

Drug / intervention	Role	Dose / use	Important adverse effects	Teaching points
Methotrexate Preferred	Anchor csDMARD, all patients without contraindication	10-15 mg PO or SC once weekly, titrate to 25 mg weekly over 4-8 weeks	GI upset, oral ulcers, hepatotoxicity, cytopenias, rare pneumonitis	Never dose more than once weekly — daily dosing has caused fatal toxicity. Co-prescribe folic acid to reduce toxicity.
Folic acid Preferred	Adjunct with every methotrexate regimen	5 mg PO once weekly (typically the day after methotrexate), or 1 mg PO daily	Well tolerated	Reduces methotrexate GI, hepatic, and mucosal toxicity without reducing efficacy.
Sulfasalazine Alternative	csDMARD monotherapy (methotrexate contraindication) or combination/triple therapy	Initial 500 mg PO daily-BID, increase by 500 mg weekly to 2-3 g/day PO in 2 divided doses	Rash, GI intolerance, bone marrow suppression, photosensitivity	Avoid in sulfa allergy or G6PD deficiency; enteric-coated tablets reduce GI upset.
Hydroxychloroquine Alternative	Mild disease monotherapy or combination/triple therapy	200-400 mg PO daily, do not exceed 5 mg/kg/day actual body weight	GI upset, rash, rare retinal toxicity	Requires baseline and scheduled ophthalmologic screening (see Monitoring).
Leflunomide Alternative	Added to or used instead of methotrexate	10-20 mg PO daily — no loading dose	Diarrhea, hepatotoxicity, hypertension, teratogenic	Contraindicated in pregnancy; requires a cholestyramine/charcoal washout before conception if stopped.
Triple therapy (combination csDMARDs) Alternative	Step-up option for methotrexate-monotherapy failure, alternative to adding a biologic/tsDMARD	Combo: methotrexate 15-25 mg PO/SC weekly + sulfasalazine 2-3 g/day PO + hydroxychloroquine 200-400 mg/day PO	Higher GI intolerance than methotrexate alone, usually improves with time	Comparable long-term efficacy to adding a biologic in trial data; a biologic/tsDMARD is conditionally preferred first for faster response, but this remains an entirely appropriate, lower-cost alternative.
Adalimumab Special situation	1st-line bDMARD class (TNF inhibitor), combined with methotrexate when possible	40 mg SC every 2 weeks	Injection-site reaction, serious infection, rare lymphoma	Complete TB and hepatitis B/C screening before starting (see Monitoring).
Tocilizumab Alternative	Alternative bDMARD class (IL-6 inhibitor); effective as monotherapy if methotrexate is contraindicated	162 mg SC weekly, or 4-8 mg/kg IV every 4 weeks	Neutropenia, elevated lipids/LFTs, rare GI perforation	Monitor neutrophils, platelets, LFTs, and lipids on the schedule in Drug Tables.
Abatacept Alternative	Alternative bDMARD class (T-cell costimulation inhibitor) after csDMARD or TNF-inhibitor failure	IV or SC per weight-based/loading schedule (see Drug Tables)	Infusion/injection-site reactions, infection	Comparable efficacy to a TNF inhibitor in head-to-head trial data.
Rituximab Special situation	Seropositive RA with inadequate response to csDMARD and a TNF inhibitor	1 g IV x2 doses, 2 weeks apart, with corticosteroid/antihistamine/acetaminophen premedication	Infusion reactions, hepatitis B reactivation, rare PML	Screen and prophylax for hepatitis B before starting; repeat only with symptom flare, usually every 6-12 months.
Tofacitinib Special situation	After inadequate response/intolerance to a bDMARD (JAK inhibitors are not preferred as the first non-csDMARD step)	5 mg PO twice daily	Serious infection, malignancy, MACE, thrombosis — boxed warning, all class members	Avoid preferring over a TNF inhibitor in patients 65 or older, smokers, or with cardiovascular risk factors/malignancy history.
Prednisone Special situation	Short-term bridging while a csDMARD reaches full effect, or for a flare	30 mg/day PO, tapering over 6-12 weeks	Hyperglycemia, hypertension, osteoporosis, adrenal suppression	Lowest effective dose for the shortest duration; not a substitute for adequate DMARD therapy.

Special Populations

Pregnancy: pregnancy itself often improves RA disease activity, though many patients still need drug therapy during all or part of pregnancy, and flares are common postpartum.^[1] Discuss family planning and adjust therapy before a planned pregnancy in every patient of reproductive age. Corticosteroids (prednisone, methylprednisolone) are considered safe throughout pregnancy. Hydroxychloroquine and sulfasalazine (with folic acid supplementation, given sulfasalazine's antifolate effect) can be continued throughout pregnancy. Certolizumab pegol is compatible with all trimesters (its pegylated antibody fragment does not cross the placenta). Adalimumab and etanercept can be continued until the end of the second trimester; infliximab until 16 weeks' gestation — discuss infant live-vaccine timing with the treating team whenever a TNF inhibitor was used in pregnancy. Methotrexate and leflunomide are contraindicated in pregnancy (methotrexate is teratogenic and abortifacient; leflunomide is teratogenic in animal studies). Avoid NSAIDs in the third trimester given antiprostaglandin effects (fetal/maternal bleeding risk, premature ductus arteriosus closure, interference with labour).

Preconception planning

Methotrexate — stop at least 3 months before attempting conception in both male and female patients; continue folic acid supplementation.
Leflunomide — contraindicated in pregnancy; if stopping to conceive, complete a drug-elimination washout (cholestyramine 8 g PO three times daily, or activated charcoal 50 g PO four times daily, for 11 days, not necessarily consecutive), then confirm plasma levels below 0.02 mg/L on 2 occasions at least 2 weeks apart before conceiving.
Sulfasalazine may affect male fertility; consider a 3-month cessation trial if the couple is having difficulty conceiving, after investigating other causes of subfertility.

Breastfeeding

Corticosteroids, hydroxychloroquine, sulfasalazine (except in an infant with hyperbilirubinemia), and NSAIDs (short-acting agents preferred) are compatible with breastfeeding. Methotrexate and leflunomide are contraindicated. Data for bDMARDs/tsDMARDs in lactation are limited; biologics have low oral bioavailability and pass into breast milk in only small amounts given their large molecular size, so use is generally considered lower-risk and decided case-by-case with the treating specialist.

Pediatric

Juvenile idiopathic arthritis is a distinct disease from adult-onset RA, with its own classification criteria and specialist-directed treatment approach — this chapter covers adult RA only. A patient with childhood-onset inflammatory arthritis needs pediatric rheumatology referral rather than adult RA dosing.

Perioperative management

Elective surgery carries an elevated infection and wound-healing-complication risk in RA. Hold a bDMARD before elective surgery, timing withdrawal so surgery falls at the end of that agent's dosing cycle, and restart once the wound shows evidence of healing (about 14 days). Hold tofacitinib or baricitinib for at least 7 days before surgery. Methotrexate, leflunomide, hydroxychloroquine, sulfasalazine, and low-dose corticosteroids can typically continue through surgery. Confirm the specific plan with the treating rheumatologist for any individual patient.^[1]

Renal/hepatic impairment

Methotrexate is contraindicated in significant renal impairment and in hepatitis B or C infection; dose-adjust or avoid csDMARDs with significant hepatic disease given shared hepatotoxicity risk. Most bDMARD/tsDMARD dosing is not renally adjusted, but active infection and hepatic/renal function must be reconfirmed before every dose escalation.

Older adults

Apply the JAK-inhibitor cardiovascular/malignancy risk stratification specifically at age 65 and older (see Red Flags & Refer and Drug Tables) — favor a bDMARD over a JAK inhibitor as the first non-csDMARD step in this group unless TNF-inhibitor therapy has already failed or was not tolerated.^[2]

Monitoring & Follow-Up

See patients at least every 3 months while disease is active; extend to every 6-12 months once well-controlled or in remission. Adjust therapy at every visit against the treat-to-target goal (see Treatment Targets) — a major regimen change (adding or switching an agent) is considered after 3 months of inadequate response to maximal current therapy; minor adjustments (a short corticosteroid course) can happen more often.^[1]

Disease activity measurement (DAS28)

The DAS28 is the most commonly used composite disease-activity measure — combining a 28-joint tender and swollen joint count, a patient global assessment, and CRP or ESR through a weighted mathematical formula. Because it uses continuously weighted terms rather than a simple point-per-criterion sum, and requires a hands-on 28-joint examination, it is a specialist/rheumatology-administered tool, not a bedside pharmacist point-of-care score — presented here as reference only, with no self-service calculator: remission is a score under 2.6, low disease activity under 3.2, moderate disease activity 3.2-5.1, and high disease activity above 5.1.

Pre-therapy and ongoing screening for bDMARD/tsDMARD therapy

Tuberculosis: assess epidemiologic risk factors, obtain a chest x-ray, and perform a Mantoux (TST) skin test before starting any bDMARD or tsDMARD; a QuantiFERON-TB Gold test can help clarify a positive screen. Exclude active TB and start isoniazid prophylaxis in anyone who screens positive before proceeding.^[1]
Hepatitis B and C serology — screen every patient before starting a bDMARD or tsDMARD, with particular attention for rituximab given its reactivation risk; antiviral prophylaxis may be required during treatment and for up to 12 months after the last rituximab dose.
Routine Pneumocystis jirovecii pneumonia prophylaxis is not required on DMARD therapy alone, unless another risk factor (e.g., high-dose corticosteroids) is also present.

Vaccination around immunosuppression

Update vaccinations before starting therapy whenever possible, particularly for any live vaccine. Live vaccines are avoided during bDMARD or tsDMARD therapy given the risk of vaccine-strain disease; inactivated/recombinant vaccines remain recommended once therapy has started, since the humoral response may be blunted but effectiveness is not meaningfully reduced.^[1]

RA therapy	Influenza (annual)	Pneumococcal	Hepatitis B	Herpes zoster (recombinant)	HPV	Live vaccines
csDMARD monotherapy	Recommended	Recommended	High-risk patients	Can consider from age 50	Recommended if otherwise indicated	Avoid
Combination csDMARDs	Recommended	Recommended	High-risk patients	Can consider from age 50	Recommended if otherwise indicated	Avoid
bDMARD or tsDMARD	Recommended	Recommended	High-risk patients	Consider case-by-case, ideally before starting	Recommended if otherwise indicated	Avoid

Use the recombinant (inactivated) herpes zoster vaccine, never the live formulation, in an RA patient on or starting immunosuppression.^[1]

Corticosteroid and bone-health monitoring

Calcium (about 1200 mg/day total intake, preferably from diet) and vitamin D (800-2000 units/day) for anyone on prolonged corticosteroid therapy; add a bisphosphonate when the corticosteroid-induced-osteoporosis risk is significant.
A single depot corticosteroid injection can cause clinically significant hyperglycemia for up to about 10 days — counsel patients with diabetes specifically.

Hydroxychloroquine retinopathy screening

Baseline ophthalmologic exam at or soon after starting (fundus exam, OCT, and wide-field fundus autofluorescence), then annual screening — deferring the first annual screen for up to 5 years is reasonable in an average-risk patient, but start annual screening immediately in a higher-risk patient (dose above 5 mg/kg/day actual body weight, treatment beyond 5 years, renal impairment, concurrent tamoxifen, or pre-existing retinal disease).^[6]

Lipid and cardiovascular monitoring

Check a lipid profile at baseline and periodically after starting an IL-6 inhibitor or JAK inhibitor (see Drug Tables for the exact schedule); do not withhold statin therapy for an inflammation-related lipid rise, since untreated RA disease activity itself independently drives cardiovascular risk beyond what standard risk calculators (e.g., Framingham) capture.^[1]

Malignancy surveillance

Apply routine age-appropriate cancer screening; use the JAK-inhibitor-specific caution in Red Flags & Refer and Special Populations for patients 65 or older, current or past smokers, or those with a malignancy history.^[2]

Treatment Failure / Next Step

Confirm methotrexate was given an adequate trial before declaring failure — maximum tolerated dose (up to 25 mg weekly) for at least 3 months, using the subcutaneous route if oral absorption or GI tolerance is a concern.
Confirm adherence and correct administration technique (weekly dosing, folic acid co-administration) — a common, reversible cause of apparent nonresponse.
Reassess disease activity with a structured measure, not symptoms alone, to confirm the patient is genuinely not at target before escalating.
If moderate-high disease activity persists on maximal tolerated methotrexate at 3 months, add a biologic or targeted synthetic DMARD (conditionally preferred) or switch to triple csDMARD therapy — complete pre-biologic screening first if escalating to a bDMARD/tsDMARD.
If inadequate response to a first TNF inhibitor, switch to a biologic with a different mechanism of action (IL-6 inhibitor, abatacept, or rituximab if seropositive) rather than cycling to a second TNF inhibitor.
If inadequate response to a second bDMARD of any class, switch again to a different mechanism, or consider a JAK inhibitor — apply the cardiovascular/malignancy risk stratification before choosing a JAK inhibitor over another biologic class.
In a patient who has sustained remission, cautious, shared-decision-making dose tapering — rather than abrupt discontinuation — of a csDMARD, bDMARD, or tsDMARD can be considered; flare risk is higher after tapering, but many patients successfully reduce therapy, and most who flare regain control after restarting the reduced or stopped agent.^[7]
At any step, re-examine the original diagnosis if response remains genuinely inadequate despite confirmed adherence and adequate trials — reconsider an alternative or overlapping diagnosis (see the differential table in Assessment & Diagnosis).

Common Errors to Avoid

Delaying DMARD initiation while trialing NSAIDs or corticosteroids alone — these control symptoms but do not modify the disease course; a csDMARD should start as soon as the diagnosis is confirmed.
Prescribing methotrexate without folic acid co-administration.
Accidentally dosing methotrexate daily instead of weekly, or giving a leflunomide loading dose — dangerous, potentially fatal errors.
Skipping tuberculosis and hepatitis B/C screening before starting a bDMARD or tsDMARD.
Giving a live vaccine to a patient on a bDMARD or tsDMARD, or failing to update vaccinations before starting significant immunosuppression.
Cycling to a second TNF inhibitor after inadequate response to the first, instead of switching to a different mechanism of action.
Choosing a JAK inhibitor over a TNF inhibitor as the first non-csDMARD step in a patient 65 or older, a current/past smoker, or with cardiovascular risk factors or a malignancy history.
Continuing a bDMARD or tsDMARD through a serious infection instead of holding it until resolution.
Exceeding the hydroxychloroquine 5 mg/kg/day actual-body-weight ceiling, or missing scheduled ophthalmologic screening.
Continuing methotrexate or leflunomide in a patient actively planning conception instead of switching to a pregnancy-compatible regimen with adequate lead time.
Combining 2 biologic agents, or a biologic with a JAK inhibitor — not well studied, and associated with increased infection risk without an established efficacy benefit.
Reaching for an opioid for RA pain instead of optimizing DMARD therapy — evidence for opioid efficacy in RA is limited, and disease-modifying treatment is the actual solution to the pain.

Clinical Decision Algorithm

Diagnosis and initial DMARD therapy

Joint swelling or inflammatory joint pain suspicious for RA: symmetric small-joint polyarthritis, morning stiffness over 30 minutes

Refer urgently to rheumatology — ideally within 6 weeks of symptom onset — for diagnosis confirmation (2010 ACR/EULAR classification criteria, RF/anti-CCP, radiographs)^[1]

No contraindication to methotrexate

Start methotrexate 10-15 mg PO/SC weekly, titrate toward 25 mg weekly over 4-8 weeks, with folic acid 5 mg weekly

Add a short bridging corticosteroid course (prednisone 30 mg/day PO tapering, or a depot IM injection) at the lowest effective dose while methotrexate takes effect^[4]

Methotrexate contraindicated (e.g., significant renal/hepatic disease, pregnancy, active infection)

Start sulfasalazine or hydroxychloroquine monotherapy instead

Reassess disease activity at 3 months — target 50% or more improvement

Treat-to-target escalation after methotrexate

Reassessment at 3-6 months

Target met: remission or low disease activity

Continue the current regimen; reassess every 3-6 months and taper the bridging corticosteroid to a stop

Moderate-high disease activity persists on maximal tolerated methotrexate

Escalate — do not simply continue methotrexate monotherapy unchanged

Add a biologic or targeted synthetic DMARD (conditionally preferred) or switch to triple csDMARD therapy (methotrexate + sulfasalazine + hydroxychloroquine) as an alternative^[5]

Before starting any bDMARD or JAK inhibitor: complete tuberculosis and hepatitis B/C screening and confirm immunizations are current — see the pre-biologic screening pathway below^[1]

Biologic and targeted synthetic DMARD selection

Inadequate response to methotrexate ± triple therapy; pre-biologic screening complete

1st-line bDMARD: a TNF inhibitor (adalimumab, certolizumab pegol, etanercept, golimumab, or infliximab) combined with methotrexate when possible — an IL-6 inhibitor or abatacept is an equally acceptable first-line class choice

Inadequate response to the 1st TNF inhibitor

Switch to a biologic with a different mechanism of action (IL-6 inhibitor, abatacept, or rituximab if seropositive) — preferred over cycling to a 2nd TNF inhibitor^[1]

Inadequate response to a 2nd bDMARD of any class

Switch to a biologic with a different mechanism again, or consider a JAK inhibitor — apply the cardiovascular/malignancy risk stratification first^[2]

Pre-biologic and pre-JAK-inhibitor screening pathway

Before initiating any bDMARD or tsDMARD

Latent TB screen positive (TST/IGRA ± chest x-ray)

Exclude active TB, start isoniazid prophylaxis, delay the bDMARD/tsDMARD start by about 1 month

HBsAg or anti-HBc positive

Hepatology referral; start antiviral prophylaxis (e.g., tenofovir or entecavir) before and during therapy, continued up to 12 months after B-cell-depleting therapy^[1]

Screening negative, immunizations current

Proceed with the selected bDMARD or tsDMARD

Drug Tables

How to use this table: Doses are adult doses and require patient-specific confirmation, including renal/hepatic adjustment. Select any drug name to open its complete Pharmasist Drug Database page.

Conventional synthetic DMARDs (csDMARDs)

Methotrexate is the anchor csDMARD for essentially every patient without a contraindication.

Drug	Dosage	Adverse effects	Drug interactions	Comments
Methotrexate	Adults: 10-15 mg PO or SC once weekly, titrate to a maximum of 25 mg weekly over 4-8 weeks Children: Not established here — juvenile idiopathic arthritis is a distinct disease with its own pediatric-rheumatology-directed dosing, outside the scope of this adult RA chapter	Nausea, malaise, flu-like aches, headache, oral ulcers, alopecia, loose stools; rare bone marrow/liver toxicity, rare pneumonitis, immunosuppression, rare malignancy	Avoid high-dose ASA and sulfonamides (e.g., high-dose trimethoprim/sulfamethoxazole); usual-dose NSAIDs and penicillins do not cause a clinically meaningful increase in low-dose methotrexate toxicity	Contraindicated in hepatitis B/C, significant renal insufficiency, and significant lung disease. Give with folic acid (5 mg weekly, typically the day after the dose, or 1 mg daily) or folinic acid (5 mg, 8-12 hours after the dose) to reduce toxicity. Oral doses above 15 mg are not well absorbed — split same-day or use the subcutaneous route. Baseline CBC, LFTs, albumin, creatinine, hepatitis B/C serology, chest x-ray; repeat CBC/LFTs/albumin/creatinine monthly for 3 months, then every 1-3 months.
Sulfasalazine	Adults: Initial 500 mg PO daily or BID, increase by 500 mg weekly to a maintenance dose of 2-3 g/day PO in 2 divided doses	Rash, bone marrow suppression, GI intolerance, photosensitivity	May decrease GI absorption of digoxin	Avoid with sulfa allergy or G6PD deficiency; enteric-coated tablets can reduce GI adverse effects. May be used in pregnancy with folic acid supplementation. Baseline CBC, LFTs, creatinine; CBC/LFTs every 3 months.
Hydroxychloroquine	Adults: 200-400 mg PO daily	Nausea, cramps, diarrhea, rash, nightmares, skin hyperpigmentation; rare dose- and duration-related retinal toxicity; rare severe hypoglycemia	Avoid concomitant QTc-prolonging agents (e.g., quinine)	Do not exceed 5 mg/kg/day actual body weight; reduce further if under 60 kg. Used as monotherapy for mild disease without poor prognostic factors, or in combination with other csDMARDs. Baseline CBC, LFTs, creatinine, and an ophthalmologic exam; annual ophthalmologic screening (see Monitoring & Follow-Up).
Leflunomide	Adults: 10-20 mg PO daily	Nausea, diarrhea, anorexia, alopecia, headache, hypertension, rash; hepatotoxicity, cytopenias, pulmonary fibrosis/interstitial lung disease	Alcohol restriction minimizes hepatotoxicity risk; combination with methotrexate increases liver/GI toxicity and requires monthly LFT monitoring and possible dose reduction of either agent	Contraindicated in pregnancy — a cholestyramine or activated-charcoal washout is required before conception if needed (see Special Populations). A loading dose is no longer recommended given significant diarrhea. Baseline CBC, LFTs, creatinine, hepatitis B/C serology; CBC/LFTs/creatinine monthly for 3 months, then every 1-3 months.

Combination csDMARD therapy

Drug	Dosage	Adverse effects	Drug interactions	Comments
Triple therapy	Combo (adults): methotrexate 15-25 mg PO/SC weekly + sulfasalazine 2-3 g/day PO in 2 divided doses + hydroxychloroquine 200-400 mg/day PO	Higher rate of GI intolerance than methotrexate monotherapy, usually improving with time	No major pharmacokinetic interaction among the 3 components; monitor each agent per its own individual schedule above	Best-evidence combination regimen for inadequate response to methotrexate monotherapy — comparable long-term efficacy to adding a biologic in trial data, though a biologic/tsDMARD is conditionally preferred first for faster symptom control per current guidance.

Tumor necrosis factor (TNF) inhibitors

Most effective when combined with methotrexate or another csDMARD. Contraindicated with serious/recurrent infection; systemic lupus erythematosus, demyelinating disease, and heart failure are relative contraindications. Complete TB and hepatitis B/C screening (chest x-ray, TST/IGRA, hepatitis serology) before starting every agent in this class.

Drug	Dosage	Adverse effects	Drug interactions	Comments
Adalimumab	Adults: 40 mg SC every 2 weeks	Injection-site reactions; infections including TB and opportunistic organisms; new-onset psoriasis; rare lymphoma/leukemia/other malignancy; autoimmune phenomena	None major beyond additive infection risk with other immunosuppressants	Given in combination with methotrexate in newly diagnosed patients when possible; can be used as monotherapy if methotrexate is contraindicated.
Certolizumab pegol	Loading: 400 mg SC at weeks 0, 2, and 4 Maintenance: 200 mg SC every 2 weeks, or 400 mg SC every 4 weeks	Same class profile as adalimumab	None major beyond additive infection risk with other immunosuppressants	The pegylated antibody fragment does not cross the placenta or into breast milk — compatible with all trimesters of pregnancy.
Etanercept	Adults: 50 mg SC once weekly, or 25 mg SC twice weekly	Same class profile as adalimumab; may increase the risk of new-onset inflammatory bowel disease	None major beyond additive infection risk with other immunosuppressants	A receptor antagonist rather than a monoclonal antibody — a distinct mechanism among the TNF inhibitors. Can be continued until the end of the second trimester in pregnancy.
Golimumab	Adults: 50 mg SC once monthly	Same class profile as adalimumab	None major beyond additive infection risk with other immunosuppressants	Once-monthly dosing on the same date each month.
Infliximab	Adults: 3 mg/kg IV at weeks 0, 2, and 6, then every 8 weeks; may increase to 10 mg/kg and/or every 4 weeks for incomplete response	Same class profile as adalimumab, plus mild-severe infusion reactions	None major beyond additive infection risk with other immunosuppressants	A chimeric mouse-human antibody given only IV; contraindicated with known hypersensitivity to murine proteins. Contraindicated in heart failure when using more than 5 mg/kg/infusion. Can be used until 16 weeks' gestation in pregnancy.

Interleukin-6 (IL-6) inhibitors

Effective as monotherapy if methotrexate is contraindicated, though combination with methotrexate is generally preferred. Complete the same pre-therapy infection screening as the TNF inhibitors.

Drug	Dosage	Adverse effects	Drug interactions	Comments
Tocilizumab	IV: 4 mg/kg every 4 weeks, infused over 1 hour; may increase to 8 mg/kg every 4 weeks for inadequate response SC, 100 kg or more: 162 mg SC weekly SC, under 100 kg: Start 162 mg SC every other week, increase to weekly based on response	Infusion/injection reactions (very severe reactions resulting in death reported rarely); serious infections; GI perforation; decreased neutrophils/platelets; elevated ALT; increased lipids	May increase CYP450 enzyme activity as inflammation is controlled — monitor concurrent therapy with drugs metabolized by CYP450 (e.g., statins, warfarin, oral contraceptives)	Baseline CBC, LFTs, creatinine, hepatitis B/C serology, TB screening; monitor neutrophils, platelets, and LFTs 4-8 weeks after starting.
Sarilumab	Adults: 200 mg SC every 2 weeks, reduce to 150 mg SC every 2 weeks for neutropenia, thrombocytopenia, or LFT elevation	Injection-site reactions; upper respiratory infections; neutropenia; elevated ALT	May increase CYP450 enzyme activity — monitor concurrent therapy with drugs metabolized by CYP450	May be used as monotherapy if methotrexate or another csDMARD/bDMARD is contraindicated. Baseline CBC, LFTs, creatinine, hepatitis B/C serology, TB screening; monitor neutrophils, platelets, and LFTs 4-8 weeks after starting; lipid profile at baseline, 4-8 weeks, and every 6 months thereafter.

T-cell costimulation inhibitor

Drug	Dosage	Adverse effects	Drug interactions	Comments
Abatacept	IV loading, under 60 kg: 500 mg IV initial infusion IV loading, 60-100 kg: 750 mg IV initial infusion IV loading, over 100 kg: 1 g IV initial infusion IV maintenance: Repeat at 2 and 4 weeks after the initial infusion, then monthly SC: 125 mg SC weekly, starting within 24 hours of the IV loading infusion, or on the same weekly schedule without an IV load	IV: minor infusion reactions. SC: injection-site reactions — rotate sites and avoid tender, bruised, red, or hard skin	None major beyond additive infection risk with other immunosuppressants	Comparable efficacy to adalimumab in head-to-head data. Baseline CBC, LFTs, creatinine, hepatitis B/C serology, TB screening.

B-cell depleting therapy

Drug	Dosage	Adverse effects	Drug interactions	Comments
Rituximab	Adults: 1 g IV x2 doses, 2 weeks apart; may repeat after 5-6 months, usually timed to symptom flare Lower-dose alternative: 500 mg IV x2 doses, 2 weeks apart — may be as effective as the standard dose	Mild-severe infusion reactions (very severe reactions resulting in death reported rarely); rare progressive multifocal leukoencephalopathy	None major beyond additive infection risk with other immunosuppressants	Most effective combined with methotrexate in RF and/or anti-CCP-positive patients with inadequate response to a csDMARD and a TNF inhibitor; contraindicated with known hypersensitivity to murine or Chinese Hamster Ovary cell proteins. Premedicate with a corticosteroid (methylprednisolone or hydrocortisone), an antihistamine, and acetaminophen. Baseline CBC, LFTs, creatinine, hepatitis B/C serology — screen carefully given reactivation risk.

Interleukin-1 (IL-1) inhibitor

Not a first-line biologic — generally less effective than other bDMARD classes and rarely used now.

Drug	Dosage	Adverse effects	Drug interactions	Comments
Anakinra	Adults: 100 mg SC daily	Injection-site reactions in up to 70% of patients, usually mild-moderate and resolving within about 1 month; infections	None major beyond additive infection risk with other immunosuppressants	Reserved for patients who are not candidates for or have not responded to preferred biologic classes.

Janus kinase (JAK) inhibitors (tsDMARDs)

All 3 agents carry a class-wide boxed warning for serious infections, malignancy/lymphoma, major adverse cardiovascular events (MACE), and thrombosis (including fatal events), extrapolated across the class from trial data comparing tofacitinib with a TNF inhibitor.<cite data-reference-id="c0b2c1c7-231f-423c-b107-84f9d9600c60"></cite> Reserve for inadequate response to, or intolerance of, a bDMARD; use with added caution — favoring a TNF inhibitor first — in patients 65 or older, current or past smokers, or those with additional cardiovascular risk factors or a malignancy history. All are metabolized by CYP450 (mainly CYP3A4) — caution with potent CYP3A4 inhibitors/inducers.

Drug	Dosage	Adverse effects	Drug interactions	Comments
Tofacitinib	Adults: 5 mg PO twice daily With potent CYP3A4 inhibitors: Reduce to 5 mg PO once daily	Infections (including TB, herpes zoster, pneumonia); serious infections leading to hospitalization or death reported; increased lymphoma/malignancy risk; GI perforation; neutropenia; increased lipids; rare hepatotoxicity at higher doses	Reduce dose with potent CYP3A4 inhibitors	Screen for latent/active TB before starting. Monitor lipids at baseline, 4-8 weeks, then every 6 months; lymphocytes/neutrophils/hemoglobin at baseline, 4-8 weeks, then every 3 months; LFTs periodically — hold if drug-induced liver injury is suspected.
Baricitinib	Adults: 2 mg PO once daily	Same class profile as tofacitinib	Caution with potent CYP3A4 inhibitors/inducers	Screen for latent/active TB before starting. Monitor lipids at baseline, 12 weeks, then every 6 months; lymphocytes/neutrophils/hemoglobin at baseline, 4-8 weeks, then every 3 months; LFTs periodically.
Upadacitinib	Adults: 15 mg PO once daily	Same class profile as tofacitinib	Caution with potent CYP3A4 inhibitors/inducers	Screen for latent/active TB before starting. Monitor lipids at baseline, 12 weeks, then every 6 months; lymphocytes/neutrophils/hemoglobin at baseline, 4-8 weeks, then every 3 months; LFTs periodically.

Corticosteroids (bridging and flare management)

Route and dose scale with need — use the lowest effective dose for the shortest duration, and pair prolonged use with the bone-health measures in Monitoring & Follow-Up.

Drug	Dosage	Adverse effects	Drug interactions	Comments
Prednisone	Bridging, DMARD initiation/change: 30 mg/day PO, tapering to discontinuation over about 6-12 weeks Chronic low-dose (not routine): 10 mg/day PO or less, only when a corticosteroid-sparing strategy has been optimized first	Hyperglycemia, hypertension, weight gain, mood change, osteoporosis, adrenal suppression, increased infection risk, avascular necrosis	Increased GI ulceration risk with NSAIDs	Preferred oral agent for bridging given its moderate potency, intermediate duration, and low mineralocorticoid activity. High-dose corticosteroid confers no added benefit over this range when starting methotrexate and carries more adverse effects.
Triamcinolone (depot IM/intra-articular)	Depot IM bridging: Single dose per product labelling, individualized to disease activity Intra-articular: Dose individualized to joint size, per product labelling	Local tissue/skin atrophy at the injection site; systemic corticosteroid effects with repeated use	Increased GI ulceration risk with NSAIDs	Depot IM injections are typically given in the gluteal muscle to reduce the lipoatrophy risk seen with superficial subcutaneous infiltration. Also used intra-articularly to manage a flare limited to a small number of joints.
Methylprednisolone sodium succinate (IV pulse)	IV pulse: Dose individualized to severity, per institutional protocol	Same systemic profile as prednisone, more pronounced with pulse dosing	Increased GI ulceration risk with NSAIDs	Reserved for higher-acuity systemic flares (e.g., extra-articular vasculitis) needing rapid control alongside starting or escalating DMARD therapy.

Adjunct and supportive therapy

Drug	Dosage	Adverse effects	Drug interactions	Comments
Folic acid	Adults: 5 mg PO once weekly (typically the day after the methotrexate dose), or 1 mg PO daily	Well tolerated	None significant	Reduces methotrexate GI, hepatic, and mucosal toxicity without reducing efficacy.
Leucovorin calcium (folinic acid)	Adults: 5 mg PO once weekly, given 8-12 hours after the methotrexate dose	Well tolerated	None significant	Alternative to folic acid, particularly useful when methotrexate adverse effects persist despite folic acid supplementation.
Naproxen	Adults: 250-500 mg PO twice daily	GI upset, GI ulceration/bleeding, cardiovascular risk	Increased bleeding with anticoagulants; reduces antihypertensive efficacy of ACE inhibitors/ARBs/diuretics	Symptom control only — no disease-modifying effect. Use the lowest effective dose for the shortest duration.
Ibuprofen	Adults: 400-600 mg PO every 6-8 hours as needed	GI upset, GI ulceration/bleeding, cardiovascular risk	Increased bleeding with anticoagulants; reduces antihypertensive efficacy of ACE inhibitors/ARBs/diuretics	Avoid preferentially in patients with known cardiovascular disease — use an alternative NSAID with low-dose ASA and gastroprotection if needed.
Diclofenac (topical)	Adults: Applied to the affected joint per product labelling, up to 4 times daily	Local skin irritation; systemic NSAID adverse effects at much lower rates than oral NSAIDs	Minimal systemic interactions given low systemic absorption	Preferred over an oral NSAID when pain is localized to 1 or a few joints, given the better systemic safety profile.
Acetaminophen	Adults: 325-1000 mg PO every 4-6 hours as needed, up to the labelled daily maximum	Hepatotoxicity at supratherapeutic doses	None significant at standard doses	An adjunct analgesic compatible with essentially every RA regimen; opioids should be avoided given limited evidence of efficacy in RA and are not a substitute for adequate DMARD therapy.

Corticosteroid-induced osteoporosis prevention

For patients on prolonged corticosteroid therapy at significant fracture risk.

Drug	Dosage	Adverse effects	Drug interactions	Comments
Calcium carbonate	Adults: Individualized to reach a total elemental calcium intake of about 1200 mg/day	Constipation, GI upset	Reduces absorption of levothyroxine, tetracyclines, and some fluoroquinolones if co-administered — separate dosing by at least 2 hours	Aim for about 1200 mg/day total elemental calcium intake, preferably from diet with supplementation making up any gap.
Vitamin D3	Adults: 800-2000 units PO daily	Well tolerated at recommended doses; hypercalcemia with excessive doses	None significant at standard doses
Alendronic acid	Adults: 70 mg PO once weekly, taken with a full glass of water while remaining upright for at least 30 minutes	Esophageal irritation, GI upset; rare osteonecrosis of the jaw or atypical femur fracture with long-term use	Calcium, antacids, and other oral medications reduce absorption — take on an empty stomach, 30 minutes before other oral intake	First-line bisphosphonate for corticosteroid-induced osteoporosis prevention when risk is significant (e.g., prednisone 7.5 mg/day or more for 6 months or longer with additional bone-loss risk factors).

Pre-biologic infection prophylaxis

Drug	Dosage	Adverse effects	Drug interactions	Comments
Isoniazid	Adults: Per current Canadian TB standards, individualized to the screening result and infectious disease/TB program guidance	Hepatotoxicity, peripheral neuropathy (reduced by co-administered pyridoxine)	Increased phenytoin levels; avoid excessive alcohol given additive hepatotoxicity	For latent TB confirmed by TB screening before starting a bDMARD or tsDMARD; give with pyridoxine to reduce neuropathy risk. Exclude active TB before starting.
Pyridoxine (vitamin B6)	Adults: 25-50 mg PO daily	Well tolerated at prophylactic doses	None significant	Co-administered with isoniazid to reduce peripheral neuropathy risk.
Tenofovir disoproxil fumarate	Adults: 300 mg PO once daily	Renal impairment, decreased bone mineral density	Avoid other nephrotoxic agents when possible; monitor renal function	Antiviral prophylaxis for a hepatitis-B-positive or previously-infected (anti-HBc-positive) patient starting a bDMARD or tsDMARD, particularly rituximab; continue through therapy and for up to 12 months after the last rituximab dose.
Entecavir	Adults: 0.5 mg PO once daily	Headache, fatigue; rare lactic acidosis	None major	Alternative antiviral prophylaxis agent for the same hepatitis B indication as tenofovir.

Leflunomide elimination (washout) protocol

Used before conception, or for significant leflunomide toxicity, to accelerate elimination of the active metabolite given its otherwise very long clearance time.

Drug	Dosage	Adverse effects	Drug interactions	Comments
Cholestyramine resin	Washout: 8 g PO three times daily for 11 days, not necessarily consecutive	GI upset, constipation, bloating	Reduces absorption of numerous oral medications, including oral contraceptives — use a non-hormonal contraceptive method during the washout	Followed by 2 plasma leflunomide-metabolite level checks at least 2 weeks apart, confirming a concentration under 0.02 mg/L, before conceiving. An activated-charcoal-based washout (specialist-directed) is an alternative when cholestyramine is not tolerated.

References

Canadian Rheumatology Association Living Guidelines for the Pharmacological Management of Rheumatoid Arthritis With Disease-Modifying Antirheumatic Drugs — The Journal of Rheumatology, Canadian Rheumatology Association (Hazlewood GS, Pardo Pardo J, Barnabe C, et al.). J Rheumatol 2022;49(10):1092-1099
Canadian labelling for all JAK inhibitors to include risks of serious heart-related problems, fatal blood clots and cancer — Health Canada. Health Canada public advisory, November 1, 2022
2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative — Arthritis & Rheumatism (Aletaha D, Neogi T, Silman AJ, et al.). Arthritis Rheum 2010;62(9):2569-2581
Canadian Rheumatology Association Living Guidelines for Rheumatoid Arthritis: Update #2 — The Journal of Rheumatology, Canadian Rheumatology Association (Nikolic RPA, Pardo Pardo J, Pope JE, et al.). J Rheumatol 2024;51(9):940-941
2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis — Arthritis Care & Research, American College of Rheumatology (Fraenkel L, Bathon JM, England BR, et al.). Arthritis Care Res (Hoboken) 2021;73(7):924-939
Special AAO Report: Recommendations on Screening for Hydroxychloroquine Retinopathy (2025 Revision) — Ophthalmology, American Academy of Ophthalmology (Marmor MF, Ahn SJ, Ehlers JP, et al.). Ophthalmology 2026;133(4):439-450
Canadian Rheumatology Association Living Guidelines for Rheumatoid Arthritis: Update #3 — The Journal of Rheumatology, Canadian Rheumatology Association (Nikolic RPA, Agarwal A, Pardo Pardo J, et al.). J Rheumatol 2026;53(8), published online March 24, 2026
Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis (ORAL Surveillance) — New England Journal of Medicine (Ytterberg SR, Bhatt DL, Mikuls TR, et al.). N Engl J Med 2022;386(4):316-326

Professional reference only. Apply clinical judgment and verify patient-specific decisions against current authoritative guidance and product information.